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These three papers have made it clear that bacter-
ial resistance is a world-wide problem, at least for
the bacterial species causing respiratory tract
infections. It is also evident that there is great
variation in the degree of resistance from country
to country and even within countries, making it
difﬁcult to generalize. There are, however, still
many unanswered questions.
There is no general agreement as to whether one
type of antimicrobial drug is more prone to pro-
moting resistance or not and it has been ques-
tioned whether a key factor here may be the
way these drugs are used. Evidence from Scandi-
navia, where a low usage of antimicrobials is
accompanied by a lack of resistance among pneu-
mococci to penicillins, would suggest that this is
so. Similarly, in Finland the link between a high
rate of prescribing of macrolides and a high level
of resistance to macrolides among GroupA strep-
tococci suggests this, especially since a reduction
in the use of macrolides was followed by a reduc-
tion in the level of resistance. Deﬁnite ‘cause and
effect’ is difﬁcult to prove, but some believe that a
change in the prescribing of certain oral third-
generation cephalosporins from four times daily
to twice daily has, by reducing the exposure of the
bacteria to effective levels of drug, encouraged the
development of resistance to penicillins in pneu-
mococci and possibly the spread of methicillin-
resistance in staphylococci.
In contrast, some antimicrobials have been used
for long periods and certain species have not
developed resistance to them. Examples quoted
include penicillins and GroupA streptococci,
and ciproﬂoxacin and Escherichia coli, Moraxella
catarrhalis and Haemophilus inﬂuenzae. Although
it is difﬁcult to understand always why this is
so, a possible or partial explanation can be found
by examining the pharmacokinetic/pharmaco-
dynamic parameters of these drugs. The most
important parameter with ﬂuoroquinolones is
believed to be the ratio of the area under the serum
concentration curve to the minimum inhibitory
concentration (MIC). For ciproﬂoxacin this ratio
is high against highly susceptible organisms (>300
for E. coli) and this could be why resistance has not
emerged, even after over 10 years of widespread
use for treating acute exacerbations of chronic
bronchitis. With b-lactam antibiotics the most
important parameter is the time above the MIC
and the high blood levels provided by penicillins
ensures that GroupA streptococci will be eradi-
cated. It was suggested that had this relatively new
science of pharmacokinetics/pharmacodynamics
been understood a decade ago, the veterinary use
of ﬂuoroquinolones would not have been
approved.
It is not easy to understand why b-lactamase
production in H. inﬂuenzae has not become univer-
sal. After a rapid initial spread some two decades
ago and widespread use of b-lactams, the inci-
dence has reached a plateau of about 30%. In
contrast, almost all M. catarrhalis strains now pro-
duce b-lactamase. Ceftriaxone, a parenteral third-
generation cephalosporin, retains activity against
many bacterial species despite widespread use for
nearly two decades. A possible explanation could
be pharmacokinetic/pharmacodynamic factors as
the bioavailability of the drug after parenteral
administration is high. Other third-generation
cephalosporins are used orally, where the limita-
tions of absorption from the gastrointestinal tract
mean that bioavailability will rarely equal that via
the parenteral route.
The detection of certain mechanisms of resist-
ance was highlighted as a problem. When a com-
pound has marginal activity, such as many
ﬂuoroquinolones against the pneumococcus, resist-
ance arises by point mutations and these can be
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difﬁcult to detect. This is particularly relevant for
ﬂuoroquinolones since ﬁrst-step mutants cannot
be detected reliably by routine laboratory MIC
determinations. As these mutants presage the
appearance of second-step mutants which have
far greater resistance, it is important that their
presence is detected. This point has not been
recognized sufﬁciently, as the literature abounds
with papers claiming that resistance among pneu-
mococci to ﬂuoroquinolones, especially the newer
ones, is rare. Most of these ﬁndings are based on
MIC determinations. If, however, some of these
strains are examined in more detail, ﬁrst-step
mutants can be found. These drugs are now
recommended in many ofﬁcial guidelines for the
treatment of community-acquired pneumonia and
unfortunately, the very patients they are recom-
mended for are those at most risk of harboring a
ﬂuoroquinolone-resistant strain.
The need for education is another important
issue. A wide range of non-infectious disease spe-
cialists prescribe antibacterials and they may have
a less detailed knowledge regarding their use.
Many countries do not spend sufﬁcient time in
training medical staff in the use of antimicrobials
and the risks of resistance if they are used indis-
criminately. Even basic hygiene, such as hand
washing, is often ignored and there is a reluctance
among many medical staff to follow guidelines.
What about the responsibility of the general pub-
lic? Education of the public can help in reducing
unnecessary claims on the practitioner to prescribe
antibiotics and in creating an understanding of the
proper use of these valuable agents. A major
change is needed in most countries on all these
aspects.
The effects of antimicrobials on the normal ﬂora
is a factor often ignored, but some believe this to be
an important point. Monitoring of the normal ﬂora
is rarely undertaken, but if it were, it could give an
early indication of changes in susceptibility to
commonly used antimicrobial agents. Penicillin-
resistant pneumococci have changes in their
penicillin-binding proteins and these strains also
contain foreign DNA believed to come from com-
mensal oral streptococci. This horizontal transfer
has been revealed by genetic analysis. Changes in
the gut ﬂora are more likely with incompletely
absorbed, orally administered drugs. At one
extreme, antibiotic-associated diarrhea can occur,
but even in the absence of diarrhea, there will be
profound changes in the gut ﬂora.
The topic of whether resistance in vitro matters
in the clinic has been touched on in all the pre-
sentations. Although there have been claims for
many years in the literature that in some instances
infections caused by strains that are resistant in
vitro to a drug do respond in the clinic, there are
now some indications that this may not always be
so. More recent studies have looked at patients
with infections caused by strains with high-level
resistance, e.g. fully penicillin-resistant pneumo-
cocci or Streptococcus pyogenes with high-level
resistance to macrolides, and found more failures
in these patients than in those infected with
strain of lower resistance. Nevertheless the evi-
dence is still sparse and many believe that resist-
ance often does not matter in the clinic other than
in some infections such as meningitis. It is import-
ant that this issue is highlighted, and clariﬁed
since high-level resistance is increasing in many
species.
Some places carry a high risk of the transfer of
strains and thus can be considered ‘dangerous’.
These include day-care centers and nursing homes
for the elderly and day-care centers and nurseries
for children. The close proximity of infants and
young children is well established as a high risk for
the transfer of resistant strains, both among the
children and also to their parents. Vaccination can
be used to limit transfer in this vulnerable group
and the new 21-valent pneumococcal vaccines are
proving effective in this respect. The circulating
strains will be replaced by others, but the vaccines
cover the strains most likely to carry resistance
determinants. Limiting the size of these establish-
ments for the elderly and for the very young could
help, as would hand washing, but neither are
always practical. The new conjugated pneumo-
coccal vaccine is now being used in the elderly
and might prove of value.
OVERALL CONCLUSIONS
The major messages from these presentations are
summarized below.
 There is a large geographic variation in re-
sistance to antimicrobial agents among vari-
ous bacterial species, which is striking, but
for which there is no simple explanation.
The reasons are almost certainly multifac-
torial. Containing resistance needs a global
strategy which looks at all aspects. There are
still many unanswered questions, despite
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numerous publications and presentations on
this topic.
 The identiﬁcation of ‘hidden’ mechanisms of
resistance is a neglected area which needs
further examination.
 Resistance should be deﬁned initially as a
clinical problem and not just as a laboratory
ﬁnding. More studies should be designed to
determine whether there genuinely is labora-
tory resistance which has no clinical impact.
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